Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bausch + Lomb Corporation Common Shares
(NY:
BLCO
)
16.49
-0.19 (-1.14%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
350,430
Open
16.34
Bid (Size)
15.00 (200)
Ask (Size)
17.00 (100)
Prev. Close
16.68
Today's Range
16.28 - 16.89
52wk Range
10.45 - 18.91
Shares Outstanding
353,800,000
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Q4 Rundown: Bausch + Lomb (NYSE:BLCO) Vs Other Medical Devices & Supplies - Specialty Stocks
April 01, 2026
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Bausch + Lomb (NYSE:BLCO) and...
Via
StockStory
Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29
March 30, 2026
From
Bausch + Lomb Corporation
Via
Business Wire
Performance
YTD
-0.5%
-0.5%
1 Month
-8.3%
-8.3%
3 Month
-0.5%
-0.5%
6 Month
+11.7%
+11.7%
1 Year
+14.9%
+14.9%
More News
Read More
3 Reasons BLCO is Risky and 1 Stock to Buy Instead
March 26, 2026
Via
StockStory
Topics
Bankruptcy
A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story
↗
March 24, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Bausch + Lomb Corp (NYSE:BLCO) Reports Mixed Q4 2025 Results: Revenue Beat, EPS Miss
↗
February 18, 2026
Via
Chartmill
Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma
March 23, 2026
From
Bausch + Lomb Corporation
Via
Business Wire
Billboard Giant Posts $1.6 Billion Revenue as $20.5 Million Bet Makes It a Top Portfolio Holding
↗
March 12, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Eye Care Giant Posts $5.1 Billion in Revenue as One Investor Builds Major Position
↗
March 12, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Bausch + Lomb Launches R&D “Teach-in” Webinar Series
March 09, 2026
From
Bausch + Lomb Corporation
Via
Business Wire
Integra LifeSciences, GE HealthCare, Bausch + Lomb, ICU Medical, and Universal Health Services Shares Are Falling, What You Need To Know
March 06, 2026
Via
StockStory
Topics
Earnings
Economy
2 Profitable Stocks Worth Investigating and 1 We Ignore
March 04, 2026
Via
StockStory
Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive
March 03, 2026
Via
Finterra
Topics
Economy
Initial Public Offering
Retirement
5 Revealing Analyst Questions From Bausch + Lomb’s Q4 Earnings Call
February 25, 2026
Via
StockStory
Topics
Earnings
Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®
February 24, 2026
From
Bausch + Lomb Corporation
Via
Business Wire
3 Small-Cap Stocks We Steer Clear Of
February 22, 2026
Via
StockStory
BLCO Q4 2025 Deep Dive: Dry Eye and Product Innovation Propel Growth, Margin Expansion in Focus
February 19, 2026
Via
StockStory
Bausch + Lomb’s (NYSE:BLCO) Q4 CY2025: Beats On Revenue
February 18, 2026
Via
StockStory
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance
February 18, 2026
From
Bausch + Lomb Corporation
Via
Business Wire
Bausch + Lomb (BLCO) Q4 Earnings: What To Expect
February 16, 2026
Via
StockStory
Topics
World Trade
3 Reasons to Sell BLCO and 1 Stock to Buy Instead
February 09, 2026
Via
StockStory
Topics
Bankruptcy
Stocks
1 Healthcare Stock to Research Further and 2 Facing Headwinds
January 29, 2026
Via
StockStory
Topics
Stocks
3 Stocks Under $50 That Fall Short
January 26, 2026
Via
StockStory
3 Cash-Burning Stocks We’re Skeptical Of
January 22, 2026
Via
StockStory
Topics
Bankruptcy
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18
January 20, 2026
From
Bausch + Lomb Corporation
Via
Business Wire
Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.
January 05, 2026
From
Bausch + Lomb Corporation
Via
Business Wire
Frequently Asked Questions
Is Bausch + Lomb Corporation Common Shares publicly traded?
Yes, Bausch + Lomb Corporation Common Shares is publicly traded.
What exchange does Bausch + Lomb Corporation Common Shares trade on?
Bausch + Lomb Corporation Common Shares trades on the New York Stock Exchange
What is the ticker symbol for Bausch + Lomb Corporation Common Shares?
The ticker symbol for Bausch + Lomb Corporation Common Shares is BLCO on the New York Stock Exchange
What is the current price of Bausch + Lomb Corporation Common Shares?
The current price of Bausch + Lomb Corporation Common Shares is 16.49
When was Bausch + Lomb Corporation Common Shares last traded?
The last trade of Bausch + Lomb Corporation Common Shares was at 04/02/26 07:00 PM ET
What is the market capitalization of Bausch + Lomb Corporation Common Shares?
The market capitalization of Bausch + Lomb Corporation Common Shares is 5.83B
How many shares of Bausch + Lomb Corporation Common Shares are outstanding?
Bausch + Lomb Corporation Common Shares has 6B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.